% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lyskjaer:168739,
author = {I. Lyskjaer and S. De Noon and R. Tirabosco and A. M. Rocha
and D. Lindsay and F. Amary and H. Ye and D. Schrimpf$^*$
and D. Stichel$^*$ and M. Sill$^*$ and C. Koelsche and N.
Pillay$^*$ and A. Von Deimling$^*$ and S. Beck and A. M.
Flanagan},
title = {{DNA} methylation-based profiling of bone and soft tissue
tumours: a validation study of the '{DKFZ} {S}arcoma
{C}lassifier'.},
journal = {The journal of pathology: clinical research},
volume = {7},
number = {4},
issn = {2056-4538},
address = {Chichester},
publisher = {Wiley},
reportid = {DKFZ-2021-01033},
pages = {350-360},
year = {2021},
note = {2021 Jul;7(4):350-360},
abstract = {Diagnosing bone and soft tissue neoplasms remains
challenging because of the large number of subtypes, many of
which lack diagnostic biomarkers. DNA methylation profiles
have proven to be a reliable basis for the classification of
brain tumours and, following this success, a DNA
methylation-based sarcoma classification tool from the
Deutsches Krebsforschungszentrum (DKFZ) in Heidelberg has
been developed. In this study, we assessed the performance
of their classifier on DNA methylation profiles of an
independent data set of 986 bone and soft tissue tumours and
controls. We found that the 'DKFZ Sarcoma Classifier' was
able to produce a diagnostic prediction for $55\%$ of the
986 samples, with $83\%$ of these predictions concordant
with the histological diagnosis. On limiting the validation
to the 820 cases with histological diagnoses for which the
DKFZ Classifier was trained, $61\%$ of cases received a
prediction, and the histological diagnosis was concordant
with the predicted methylation class in $88\%$ of these
cases, findings comparable to those reported in the DKFZ
Classifier paper. The classifier performed best when
diagnosing mesenchymal chondrosarcomas (CHSs, $88\%$
sensitivity), chordomas $(85\%$ sensitivity), and fibrous
dysplasia $(83\%$ sensitivity). Amongst the subtypes least
often classified correctly were clear cell CHSs $(14\%$
sensitivity), malignant peripheral nerve sheath tumours
$(27\%$ sensitivity), and pleomorphic liposarcomas $(29\%$
sensitivity). The classifier predictions resulted in
revision of the histological diagnosis in six of our cases.
We observed that, although a higher tumour purity resulted
in a greater likelihood of a prediction being made, it did
not correlate with classifier accuracy. Our results show
that the DKFZ Classifier represents a powerful research tool
for exploring the pathogenesis of sarcoma; with refinement,
it has the potential to be a valuable diagnostic tool.},
keywords = {bone (Other) / classifier (Other) / methylation profiling
(Other) / sarcoma (Other) / soft tissue (Other)},
cin = {B300 / HD01 / B062},
ddc = {610},
cid = {I:(DE-He78)B300-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)B062-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:33949149},
doi = {10.1002/cjp2.215},
url = {https://inrepo02.dkfz.de/record/168739},
}